Jiangxi Bio Pivots to Animal Health, Launching Major Antitoxin Facility

HONG KONG – July 27, 2026 – Jiangxi Institute of Biological Products Inc., a global leader in human antiserum, has officially launched production at its new veterinary pharmaceutical facility, a landmark move that signals a major strategic shift into the rapidly growing animal health sector. The production line for Veterinary Tetanus Antitoxin (Veterinary TAT), operated by the company's wholly-owned subsidiary Chifeng Bo-en Pharmaceutical Co., Ltd., commenced operations on July 20 in Chifeng City, Inner Mongolia.

This launch is the most significant milestone to date in Jiangxi Bio's “human pharmaceuticals + veterinary pharmaceuticals” dual-wheel-driven strategy. By expanding its formidable antiserum portfolio from human to animal applications, the company is not only diversifying its revenue streams but also positioning itself to become a comprehensive leader across the broader biopharmaceutical landscape.

A Strategic Leap into a Booming Market

Jiangxi Bio's entry into the veterinary space is a calculated move to capitalize on a thriving global industry. The animal health market was valued at over $51 billion in 2024 and is projected to surge to nearly $86 billion by 2034, driven by powerful secular trends. In China, the growth is even more pronounced, with the market expected to more than double from RMB 68.0 billion in 2024 to RMB 141.0 billion by 2034, registering a compound annual growth rate (CAGR) of 7.6%.

The demand is fueled by two parallel forces: the increasing “humanization” of pets and the growing global need for safe animal protein. As pet ownership rises, particularly in markets like China where the companion animal health market is expanding at over 11% annually, owners are spending more on advanced healthcare, including preventative treatments and biologics. Simultaneously, the industrialization of livestock farming to feed a growing global population necessitates robust health solutions to ensure food safety and productivity. The veterinary biological products segment, which includes vaccines and antisera like TAT, is a key beneficiary, with projections showing it will grow from approximately $18 billion in 2024 to nearly $26 billion by 2034 globally.

By establishing a large-scale production base for veterinary products, Jiangxi Bio is building the capacity to meet this escalating demand, effectively de-risking its business from reliance on a single market and creating a powerful new engine for growth.

Leveraging Decades of Human Antiserum Dominance

While this is a new venture, Jiangxi Bio is not starting from scratch. The company is a titan in the human antiserum field, with a history tracing back to 1969. In 2025, it was the largest provider of human tetanus antitoxin globally, commanding an astonishing 45.8% of the market. In China, its dominance is even more stark, having held a 65.8% market share for 19 consecutive years.

This deep-seated expertise is the cornerstone of its new strategy. The company is transferring decades of accumulated knowledge in technology, manufacturing processes, and stringent quality management from its human biologics division to its veterinary arm. This is made possible by what the group calls its “globally rare fully-industry-chain antiserum integration platform,” a vertically integrated system that includes everything from equine immunization farms to advanced plasma processing facilities. This ensures a traceable, high-quality supply chain that is difficult for competitors to replicate.

The new Chifeng Bo-en facility itself is a testament to this commitment to quality. It was built to comply with China's rigorous new Veterinary Drug GMP standards as well as international benchmarks, including the European Union’s GMP and the US FDA’s quality system requirements. This high level of compliance not only solidifies its position in the domestic market but also paves the way for future exports, leveraging the company's existing global sales network that already spans over 30 countries.

Safeguarding Animal Health with an Eye on Innovation

Veterinary Tetanus Antitoxin is a critical tool for animal health, used for the prevention and treatment of tetanus—a potentially fatal infectious disease caused by toxins from the Clostridium tetani bacterium, often following trauma or surgery in both livestock and pets. By providing passive immune protection, Veterinary TAT can be a life-saving intervention. The commencement of this production line promises to enhance the supply of this essential product, benefiting veterinarians, farmers, and pet owners alike.

However, the company’s ambitions extend far beyond a single product. The Chifeng facility is equipped with eight modern production lines capable of producing a diverse range of products, including antisera, cell fermentation products, biological extracts, and chemical preparations. The product portfolio already includes items like Recombinant Interferon-α, Pig Spleen Transfer Factor, and various reproductive hormones. This indicates a broader strategic focus on key veterinary fields such as anti-infectives, immunomodulation, and reproductive management.

In a statement, the Group’s management articulated this vision: “The successful commencement of production of the Veterinary TAT production line marks an important step in advancing Jiangxi Bio's ‘human + veterinary’ dual-flywheel-driven strategy from product planning to industrial-scale commercialization... Looking ahead, the Group will continue to advance the research, development and commercialization of products in the fields of veterinary reproduction and anti-infection, contributing Jiangxi Bio's strength to the cause of global animal health.”

This forward-looking approach positions the company to compete not just on established products but also on the next wave of biotechnological innovations in animal medicine, navigating a path similar to the evolution seen in human therapeutics. While Jiangxi Bio enters a field populated by established giants like Zoetis, Merck, and Boehringer Ingelheim, its unique combination of deep specialization in antisera, a fully integrated production chain, and a dual-market strategy provides a compelling foundation for carving out a significant share of the global animal health market.